Navigation Links
Anti Allergy Drugs Reduce Tumor Growth

ent, compared to control animals.

No one knows exactly how cromolyn works to control allergies. However, Dr. Logsdon has found that cromolyn can bind a specific protein produced by cancer cells and block that protein's ability to interact with a receptor that stimulates cancer cell growth, survival, and spreading. The relationship between how the drug controls allergies and its anti-tumor effect in pancreatic cancer remains unclear. "It may be possible that cromolyn has more than one target that influences cancer," he says.

Logsdon discovered the cancer-stimulating protein, determined how it triggers tumor growth and spread, and identified cromolyn as an inhibitor. "Through serendipity and basic science sleuthing we may now have something that helps patients," he says.

The study culminates Logsdon's five-year search for an agent to treat pancreatic cancer.

Logsdon searched for genes that produced proteins secreted only by cancer cells, which would then loop around and act on the cancer cell through a receptor on the cell surface. "That way, we could have two potential drug targets - the secreted protein and the receptor," he said.

Out of a long list of such genes, Logsdon and his research team selected one called "S100P" because it is a member of the large S100 gene family, some of which produce secreted proteins and some of which are associated with other cancers. Further work showed that S100P over-expression was very specific to pancreatic cancer; the protein was not found in normal pancreatic cells. "It is important to embryonic development, but no one knows its physiological role in adult biology," he says.

By using gene-silencing techniques, Logsdon found that when the protein is disabled, cancer growth is slowed. "S100P plays a role in tumor development because it causes cancer cells to grow faster, survive better, and be more invasive," he says.

Logsdon found that S100P interacts with a re
'"/>




Page: 1 2 3

Related medicine news :

1. Allergy Risk Increased by Kerosene Use
2. Infant Fevers Found to Reduce Allergy Risk Later In Life
3. A Common Cause Of Allergy That Goes Unnoticed
4. Laser Surgery for Allergy
5. The Efficacy Of Allergy Shots Questioned
6. Oral Edible vaccine for Allergy Vaccines
7. Tattoo Wearers Are More Prone To Allergy Risks
8. A Sneak Preview of Human’s Susceptibility to Auto Immune Disease, Allergy, Asthm
9. Allergy Alarm: Sams Choice Milk Chocolate Turns Bitter with Undisclosed Nuts
10. Hope for Dust Mite Allergy Sufferers
11. Effective Vaccine Found For Dust Mite Allergy
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Anti Allergy Drugs Reduce Tumor Growth

Breaking Medicine Technology:For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain 2For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain 3Genoptix Announces Participation at Deutsche Bank 2009 MedTools Investor Conference 2Merieux Alliance Becomes Institut Merieux 2Merieux Alliance Becomes Institut Merieux 3Merieux Alliance Becomes Institut Merieux 4Novartis Receives FDA Approval for Valturna 28R 29 a Single Pill Combination of valsartan and aliskiren to Treat High Blood Pressure 57565 1Novartis Receives FDA Approval for Valturna 28R 29 a Single Pill Combination of valsartan and aliskiren to Treat High Blood Pressure 57565 2Novartis Receives FDA Approval for Valturna 28R 29 a Single Pill Combination of valsartan and aliskiren to Treat High Blood Pressure 57565 3Novartis Receives FDA Approval for Valturna 28R 29 a Single Pill Combination of valsartan and aliskiren to Treat High Blood Pressure 57565 4Novartis Receives FDA Approval for Valturna 28R 29 a Single Pill Combination of valsartan and aliskiren to Treat High Blood Pressure 57565 5Novartis Receives FDA Approval for Valturna 28R 29 a Single Pill Combination of valsartan and aliskiren to Treat High Blood Pressure 57565 6Novartis Receives FDA Approval for Valturna 28R 29 a Single Pill Combination of valsartan and aliskiren to Treat High Blood Pressure 57565 7TCT 2009 to Feature vProtect 28TM 29 Luminal Shield a Novel Treatment Designed for Soft Coronary Lesions from Prescient Medical 14134 1TCT 2009 to Feature vProtect 28TM 29 Luminal Shield a Novel Treatment Designed for Soft Coronary Lesions from Prescient Medical 14134 2Photo 3A Novartis Receives FDA Approval for Valturna 28R 29 a Single Pill Combination of valsartan and aliskiren to Treat High Blood Pressure 14132 1Photo 3A Novartis Receives FDA Approval for Valturna 28R 29 a Single Pill Combination of valsartan and aliskiren to Treat High Blood Pressure 14132 2Photo 3A Novartis Receives FDA Approval for Valturna 28R 29 a Single Pill Combination of valsartan and aliskiren to Treat High Blood Pressure 14132 3Photo 3A Novartis Receives FDA Approval for Valturna 28R 29 a Single Pill Combination of valsartan and aliskiren to Treat High Blood Pressure 14132 4Photo 3A Novartis Receives FDA Approval for Valturna 28R 29 a Single Pill Combination of valsartan and aliskiren to Treat High Blood Pressure 14132 5Photo 3A Novartis Receives FDA Approval for Valturna 28R 29 a Single Pill Combination of valsartan and aliskiren to Treat High Blood Pressure 14132 6Photo 3A Novartis Receives FDA Approval for Valturna 28R 29 a Single Pill Combination of valsartan and aliskiren to Treat High Blood Pressure 14132 7